show episodes
 
Showcasing major breakthroughs in cancer care from worldwide clinical trials, Project Oncology® educates and assists the healthcare professionals who dedicate their lives to helping patients fight cancer. Here you’ll find leading oncologists discuss and share essential cancer care strategies for all different types of cancer. And as worldwide clinical trials continue to explore new screening tests and discover novel treatment options, you can rest assured that you’ll always catch the latest ...
  continue reading
 
Artwork

1
JCO Oncology Practice Podcast

American Society of Clinical Oncology (ASCO)

icon
Unsubscribe
icon
Unsubscribe
Monthly
 
JCO OP: Put Into Practice highlights new research published in JCO OP related to cancer care delivery, quality, disparities, access. Host Dr. Fumiko Chino, MD FASCO interviews thought leaders in oncology to give listeners practical knowledge that can be used in day-to-day practice along with solution-oriented discussions and care innovations.
  continue reading
 
Artwork

1
AACR Scientific Podcasts

American Association for Cancer Research (AACR)

icon
Unsubscribe
icon
Unsubscribe
Monthly
 
In the American Association for Cancer Research (AACR) scientific podcasts, we provide interviews with cancer researchers about their latest work as well as recordings of AACR teleconferences.
  continue reading
 
Artwork

1
Standing Ready

Department of Veterans Affairs

icon
Unsubscribe
icon
Unsubscribe
Monthly
 
Welcome to Standing Ready: An Inside Look at the Untold History of the VA's Medical Innovations. Join us as we elevate and highlight significant medical and scientific contributions of the nation's largest healthcare system. Join us for interviews with VHA innovators and pioneers, exploring how VHA has changed the landscape of medicine over 75 years with topics on the history of prosthetic limbs, adaptive sports, how history has influenced VHA’s response to the COVID-19 pandemic, and more! T ...
  continue reading
 
Loading …
show series
 
Dr. Fumiko Chino talks with Dr. Aditi Singh and patient advocate Liz Salmi about how this essential tool for documentation could be optimized to be more patient-centered. This discussion will be based off the JCO OP article published in late 2024, “Re-Envisioning the Electronic Health Records to Optimize Patient-Centered Cancer Care, Quality, Surve…
  continue reading
 
Host Dr. Shannon Westin and guests Dr. Bill Aronson discuss the article "High Omega-3, Low Omega-6 Diet With Fish Oil for Men With Prostate Cancer on Active Surveillance: The CAPFISH-3 Randomized Clinical Trial" and how Omega-6 are predominant in the American diet while the study significantly lowered the intake of Omega- 6 fats. TRANSCRIPT Dr. Sha…
  continue reading
 
Discover an easy Introduction to the Software Development Life Cycle (SDLC) in this video! Aleksandr Gushchin, a Delivery Manager for big clients, breaks down the SDLC in software engineering with a simple, clear approach. Learn the fundamentals, explore SDLC models, and uncover best practices that drive engineering excellence. In just 40 minutes, …
  continue reading
 
In this JCO Article Insights episode, Ece Cali summarizes findings from the JCO article, "Datopotamab Deruxtecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non–Small Cell Lung Cancer: The Randomized, Open-Label Phase III TROPION-Lung01 Study." TRANSCRIPT Ece Cali: Hello and welcome to the JCO Article Insights. I'm your host Ece …
  continue reading
 
Host Dr. Fumiko Chino sits down with co-editor and health outcomes researcher Dr. Ryan Nipp, and contributing author Dr. Kelly Shanahan who is living with metastatic breast cancer to have a candid conversation about financial toxicity, the lived experience for patients, and what we can do to move the needle on affordability in cancer care. TRANSCRI…
  continue reading
 
Host Dr. Davide Soldato and his guests Dr. Ann Wu and Dr. Alexa White discuss the article "Air Pollution and Breast Cancer Incidence in the Multiethnic Cohort Study" and the editorial "Growing Evidence for the Role of Air Pollution in Breast Cancer Development" TRANSCRIPT The guests on this podcast episode have no disclosures to declare. Dr. Davide…
  continue reading
 
Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Matthew Matasar, MD When treating relapsed or refractory large B-cell lymphoma (R/R LBCL) with CAR T-cell therapy, the risk of adverse events is a key consideration. Models such as PhasED-Seq and CAR-HEMATOTOX can help clinicians assess the patient’s risk and personalize care plans regarding treatment…
  continue reading
 
Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Sairah Ahmed, MD Guest: Caron A. Jacobson, MD The side effects associated with CAR T-cell therapy are very different than those seen with other cancer therapies and include cytokine-release syndrome (CRS) and neurotoxicity. It’s important to know how to recognize the signs of these adverse events and …
  continue reading
 
Host: Jacob Sands, MD Guest: Julia Rotow, MD In non-squamous non-small cell lung cancer (NSCLC), a small percentage of patients will have activating HER2 mutations. For these patients, the standard second-line therapy is docetaxel, but this can have poor response rates. That’s why the DESTINY-Lung03 trial examined the safety and efficacy of trastuz…
  continue reading
 
Guest: Tara Graff, DO, MS Host: Charles Turck, PharmD, BCPS, BCCCP While CAR T-cell therapy is an effective option for patients with certain blood cancers like lymphoma and myeloma, it’s associated with two common adverse events: cytokine release syndrome and neurotoxicity. Given those risks, safety protocols have evolved over time to include strat…
  continue reading
 
Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Laura Alder, MD The recent approval of antibody drug conjugates (ADCs) has the potential to address unmet needs associated with second-line treatment options for non-small cell lung cancer, like limited benefits and substantial toxicity. But given the complex structure of ADCs, it’s important to ident…
  continue reading
 
In this JCO Article Insights episode, Giselle de Souza Carvalho provides a summary on "Navigating Treatment Pathways in Metastatic Hormone Receptor–Positive, HER2-Negative Breast Cancer: Optimizing Second-Line Endocrine and Targeted Therapies" by Bhardwarj, et al and "US Food and Drug Administration Approval Summary: Capivasertib With Fulvestrant f…
  continue reading
 
Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Thomas Egenod, MD In an effort to identify additional treatment options for resectable non-small cell lung cancer (NSCLC), the NeoCOAST-2 study is evaluating the efficacy and safety of combining durvalumab, chemotherapy, and novel agents in the neoadjuvant setting as well as combining durvalumab with …
  continue reading
 
Host: Jacob Sands, MD Guest: Aaron Lisberg, MD Unfortunately, brain metastases are very common in patients with non-small cell lung cancer (NSCLC). That’s why the phase 3 TROPION-Lung01 trial examined the efficacy and safety of datopotamab deruxtecan (Dato-DXd) for advanced non-squamous NSCLC with brain metastases. Joining Dr. Jacob Sands to share …
  continue reading
 
Host: Jacob Sands, MD Guest: Aaron Lisberg, MD Docetaxel alone or in combination with ramucirumab is the current standard of care for the second-line treatment of non-small cell lung cancer (NSCLC), but there are several limitations of docetaxel-containing regimens. That’s why there’s interest in identifying new therapies like datopotamab deruxteca…
  continue reading
 
Host: Jacob Sands, MD Guest: Alex Spira, MD, PhD, FACP Valemetostat is a novel therapy that’s demonstrated clinical efficacy and safety across multiple hematologic malignancies, but what role might it have in treating patients with advanced, unresectable, or metastatic non-squamous non-small cell lung cancer (NSCLC)? To find out, an upcoming trial …
  continue reading
 
In this episode of "Interview Anywhere," we explore data structures and algorithms coding interview questions and answers. This episode will be helpful for beginners as well as for experts with more than four years of experience. Watch as Pratik Jagtap, our candidate, solves coding challenges and handles in-depth questions from our expert interview…
  continue reading
 
Guest: Cheryl Maier MD, PhD Heparin resistance occurs when patients don’t respond to anticoagulation as expected, even with what seems like the appropriate dose. Join Dr. Cheryl Maier, who spoke about this topic at the 2024 American Society of Hematology Annual Meeting, to learn more about testing methods, the role of antithrombin, and alternative …
  continue reading
 
Guest: Michele Lambert, MD, MSTR New treatments are on the horizon for patients with immune thrombocytopenia (ITP). Dr. Michele Lambert shares insights on how BTK inhibitors and immune-targeting drugs aim to address the root causes of ITP and offer more personalized care for patients. Dr. Lambert, the Medical Director of the Special Coagulation Lab…
  continue reading
 
Guest: Michael Gonzalez, PhD, MSc New research on the molecular mechanisms behind idiopathic multicentric Castleman disease (iMCD) through gene expression analysis of lymph node tissue has the potential to improve both diagnosis and treatment. Join Dr. Michael Gonzalez as he dives in on his recent findings, which he spoke about at the 2024 American…
  continue reading
 
Host: Jacob Sands, MD Guest: Marina Garassino, MD Datopotamab deruxtecan (Dato-DXd) is a second-line antibody drug conjugate that could lead to improved progression-free survival in patients with advanced or metastatic non-small cell lung cancer. Given these potential benefits, it’s important to identify biomarkers that may predict a patient’s resp…
  continue reading
 
Loading …

Quick Reference Guide

Listen to this show while you explore
Play